ERBB2 and non-small cell lung carcinoma: Among the several next-generation tyrosine kinase inhibitors (TKIs) tested against uncommon EFGR alterations, poziotinib has been demonstrated to be a powerful agent for metastatic non-small-cell lung cancer (mNSCLC) with aberrations in <i>HER2</i> exon 20, and FDA approval is being sought in the previously-treated population.